- If the patient is over 152.4 cm in height AND over 50kg for males/45.5 kg for females, use the Dosing Body Weight (DBW) calculator below.
- Dosing Body Weight = Actual Weight if the patient does not meet the criteria above.
- For pregnant patients, the pre-pregnancy weight shall be used for Dosing Body Weight calculations.
- Pre-pregnancy weight = Actual Weight in the calculator below
Patient must meet 1 of the following 3 criteria:
- major bleeding and platelet count less than 50 x 109/L; or
- failed to respond to steroids after 3 or more days
- produce an increase in platelet count to a level considered safe
Dose
Acute:
1g/kg per day for 1 or 2 consecutive days depending on response
Chronic:
1-2 g/kg no more frequently than every 2 weeks
Must meet 1 of the following 3 criteria:
- there is major bleeding
- when platelet counts fall below 10 x 109/L, anytime in the pregrancy OR
10-30x109/L during the second or third trimester. - rapid elevation of platelets required before delivery or any invasive procedure (e.g. amniocentesis)
Dose
1 g/kg per day for 2 consecutive days (dosing body weight is based on the pre-pregnancy weight for determining IVIG dose; no maximum dose)
Order must be in consultation with a Hematologist
Dose
IVIG dose: 0.4g/kg every 3 to 4 weeks
SCIG dose: 0.1 to 0.13g/kg every week
No criteria are required other than a diagnosis of PTP
Dose
1 g/kg repeat if necessary
Order must be in consultation with a Hematologist
Dose
2 g/kg divided over 2 to 5 days
Order must be in consultation with a Hematologist
Dose
2 g/kg divided over 2 to 5 days
Patient must be resistant to stereoids and exhibit symptomatic anemia
Dose
up to 2 g/kg
Patient must meet both of the following criteria:
- Mother has been found to have anti-platelet alloantibodies through a prior affected pregnancy or close family member (e.g. sister) with an affected pregnancy
AND - Treatment is under the direction of a maternal fetal medicine center
Dose
1 to 2g/kg per week throughout the pregnancy (dosing body weight is based on pre-pregnancy weight for determining IVIG dose; disease severity also considered; no maximum dose)
Order must be in consultation with a Rheumatologist, Hematologist or General Internist
Dose
2 g/kg divided over 2 to 5 days
Order must be in consultation with an Immunologist, Hematologist, General Internist or Infectious Disease Specialist
Monitor IgG trough level every 3 to 6 months to maintain 7 - 10g/L in most patients
Dose
IVIG dose: 0.4 to 0.7g/kg every 3 to 4 weeks
SCIG dose: 0.1 to 0.23g/kg every week
Patient has/had recent life threatening or recurrent clinically significant infection(s) related to low levels of polyclonal immunoglobulin.
Dose
IVIG dose: 0.4 to 0.7g/kg every 3 to 4 weeks
SCIG dose: 0.1 to 0.23g/kg every week
Patient must meet both of the following criteria:
- has failed to respond or has contraindications to high dose antihistamines
AND - failed to respond or has contraindications to Omalizumab® (if covered)
Dose
Induction dose: 1 g/kg per day for 3 days
Maintenance dose: 1 g/kg every 4 weeks
Order must be in consultation with a Neurologist
Dose
IVIG dose: 2g/kg divided over 2 to 5 days
Maintenance dose: 1g/kg every 2 to 6 weeks
SCIG dose: 0.2 to 0.4g/kg every week
Patient must meet both of the following criteria:
- IVIG is being given within 2 weeks of the symptoms onset
AND - Hughes Disability score of 3 or more or less than 3 with symptoms progressing
Hughes Disability Scale:
| Grade | Description |
| 0 | healthy |
| 1 | minor signs or symptoms, able to run |
| 2 | able to walk 5 m independently |
| 3 | able to walk 5 m with a walker, stick, or one-person support |
| 4 | bed- or chair-bound |
| 5 | Requiring assisted ventilation |
Dose
2 g/kg divided over 2 to 5 days
NO criteria are required other than a diagnosis of MMN
Dose
IVIG dose: 2g/kg divided over 2 to 5 days
Maintenance dose: 1g/kg every 2 to 6 weeks
SCIG dose: 0.2 to 0.4g/kg every week
Patient must meet 1 of the following 2 criteria:
- Pregnant/immediate post partum period when other immunomodulation is contraindicated
OR - relapsing/remitting MS who fail or have contraindications to standard immunomodulatory therapies
Dose
1 g/kg monthly with or without a 5 day induction of 0.4 g/kg daily
Patient must meet 1 of the following 3 criteria
- acute exacerbation (myasthenic crisis)
OR - optimization prior to surgery and/or thymectomy
OR - as maintenance therapy for moderate to severe MG in combination with immunosuppressive agents
Dose
IVIG dose: 2g/kg divided over 2 to 5 days every 4 to 6 weeks
SCIG dose: 0.2 to 0.4g/kg every week
Patient has failed or has contraindications to GABAergic medications
Dose
2 g/kg divided over 2 to 5 days every 4 to 6 weeks
Patient must meet both of the following criteria:
- cared for in consultation with a Neurologist
AND - used in conjuction with immunosupressives and/or plasmapheresis
Dose
2 gk/kg divided over 2 to 5 days
IVIG is used as a short term temporizing measure
Dose
2 g/kg divided over 2 to 5 days
Patient has failed or has contraindications to steroids
Dose
2 g/kg divided over 2 to 5 days
Order must be in consultation with a Neurologist
Dose
Induction dose: 2 g/kg in 2 to 5 divided doses
Maintenance dose: 0.4 to 1 g/kg every 2 to 6 weeks
Patient has failed or has contraindications to plasma exchange and/or steroids
Dose
1-2 g/kg in 2 to 5 divided doses
Patient must meet both of the following criteria:
- treated withing 1 month of symptom onset
AND - used in conjuction with chemotherapy treatment
Dose
2 g/kg every 4 to 6 weeks
Patient has failed or has contraindications to immunosuppressive therapy
Dose
2g/kg in 2 to 5 divided doses
Maintenance dose: 1g/kg every 4 to 6 weeks
Patient failed to respond or has contraindications to corticosteroids.
Dose
0.4 g/kg/day for 5 consecutive days every 4 weeks
Order must be in consultation with a Dermatologist
Dose
2 g/kg every 4 weeks
Patient must meet both of the following criteria
- Has failed to respond or has contraindications to high dose antihistamines
AND - Failed to respond or has contraindications to Omalizumab®(if covered)
Dose
Induction dose: 1 g/kg/day for 3 days
Maintenance dose: 1 g/kg every 4 weeks
Patient must meet both of the following criteria:
- Has significant muscle weakness
AND - Failed to respond or has contraindications to corticosteroids
Treatment is prescribed by a Dermatologist
Dose
2 g/kg divided over 2 to 5 days
Patient failed to respond or has contraindications to corticosteroids.
Dose
2 g/kg every 4 weeks
Patient must meet both of the following criteria.
- Cared for in consultation with a Dermatologist
AND - Failed to respond or has contraindications to systemic steroids
Dose
2 g/kg every 4 weeks
(Pemphigus vulgaris, Pemphigus foliaceus, Pemphigoid, Cicatricial Pemphigoid, Linear IgA disease, Epidermolysis bullosa acquisita, Pemphigoid gestationis)
Patient must meet both of the following criteria.
- Disease is rapidly progressing
AND - Failed to respond or has contraindications to systemic steroids
Treatment is presribed by a Dermatologist
Dose
2 g/kg every 4 weeks
Patient failed to respond or has contraindications to corticosteroids
Dose
2 g/kg every 4 weeks
Patient must meet 1 of the following 2 criteria
- Failed to respond or has contraindications to corticosteroids with/without immunosuppressive therapies
OR - The presence of life-threatening disease
Dose
Initial dose: 2 g/kg divided over 2 to 5 days every 4 to 6 weeks
Taper when disease stable
Order must be in consultation with a Rheumatologist or Hematologist
Dose
2 g/kg divided over 2 to 5 days
Order must be in consultation with a Rheumatologist
Dose
2 g/kg divided over 2 to 5 days
Order must be in consultation with a Rheumatologist
Dose
2 g/kg divided over 2 to 5 days
Order must be in consultation with a Rheumatologist, Hematologist or General Internist
Dose
2 g/kg divided over 2 to 5 days
Order must be in consultation with a Rheumatologist
Dose
2 g/kg divided over 1 to 2 days
Patient must be treated with a combination therapy of antibiotics and IVIG
Dose
1 g/kg on day 1 and 0.5 g/kg per day on days 2 and 3 OR 0.15 g/kg per day for 5 days
Patient must be treated with a combination therapy of antibiotics and IVIG
Dose
1 g/kg on day 1 and 0.5 g/kg per day on days 2 and 3 OR 0.15 g/kg per day for 5 days
Immunocompromised patient with parvovirus B19 causing Pure Red Cell Aplasia
Dose
Initial dose: 0.4 to 1 g/kg for 5 to 10 days
Maintenance dose: 0.4 g/kg every 4 weeks
1. Susceptible pregnant individuals OR immunocompromised individuals 6 months of age and older
AND
2. IVIG should only be provided within 6 days of measles exposure
Dose
0.4/kg given once
Patient must meet the following criterion: Pathology proven acute antibody mediated rejection
Dose
IVIG is commonly administered as part of a treatment protocol that includes plasmapheresis. 0.2 g/kg after each plasmapheresis session up to a total of 10 doses (i.e. 2 g/kg maximum cumulative dose) then reassess. Additional doses may be required depending on response.
Immunocompromised patient with parvovirus B19 causing Pure Red Cell Aplasia
Dose
Initial dose to: 0.4 to 1 g/kg for 5 to 10 days
Maintenance dose to: 0.4 g/kg every 4 weeks
Immunocompromised patient with a pathological diagnosis of BK Polyomavirus
Dose
0.2g/kg per week for 5 doses (i.e.1g/kg maximum cumulative dose) then reassess. Additional doses may be required depending on response
Treatment includes consultation with or is within a high-risk neonatal center
Dose
1 g/kg per day x 2 days
Total serum bilirubin (TSB) rising despite intensive phototherapy
Dose
0.5 to 1 g/kg, with repeat dosing every 12-24 hours as necessary
Patient must meet 1 of the following 2 criteria:
- Platelets less than 50 x 109/L AND either the presence of major bleeding or surgery required
OR - Platelets less than 20 x 109/L AND treatment clinically indicated
Dose
0.8 to 1 g/kg, with a 2nd dose within 48 hours if the platelet count has not increased to above 20 x 109/L
Patient must meet 1 of the following 2 criteria:
- Platelets less than 50 x 109/L
OR - Imaging evidence of intracranial hemorrhage or other serious bleeding
Dose
1 g/kg daily for 2 days with a second dose of 1 g/kg if platelet count is still less than 30 x 109/L
Patient must meet criteria number 1 and either criteria number 2 or 3:
- Acquired hypogammaglobulinemia
PLUS - History of severe invasive or recurrent sinopulmonary infections
OR - Registered on a protocol which requires IVIG support
Dose
0.4 to 0.6 g/kg every 3 to 4 weeks
Order must be in consultation with a pediatric Hematologist
Dose
IVIG dose: 0.4 g/kg every 3 to 4 weeks
SCIG dose: 0.1 to 0.13g/kg every week
Order must be in consultation with a Pediatric Hematologist
Dose
0.4 to 0.6g/kg every 3 to 4 weeks
Order must be in consultation with an Immunologist
Dose
IVIG dose: 0.4 to 0.7 g/kg every 3 to 4 weeks
SCIG dose: 0.1 to 0.23 g/kg every week
Order must be in consultation with an Immunologist or a Hematologist
Dose
IVIG dose: 0.4 to 0.7 g/kg every 3 to 4 weeks
SCIG dose: 0.1 to 0.23 g/kg every week
Patient must meet both of the following criteria:
- IVIG is being given within 2 weeks of symptom onset
AND - Hughes Disability score of 3 or more or less than 3 with symptoms progressing
| Grade | Description |
| 0 | healthy |
| 1 | minor signs or symptoms, able to run |
| 2 | able to walk 5 m independently |
| 3 | able to walk 5 m with a walker, stick, or one-person support |
| 4 | bed- or chair-bound |
| 5 | Requiring assisted ventilation |
Dose
2 g/kg divided over 2 to 5 days
Patient must meet 1 of the following 3 criteria:
- Acute exacerbation (myasthenic crisis)
OR - Optimization prior to surgery and/or thymectomy
OR - As maintenance therapy for moderate to severe MG in combination with immunosuppressive agents
Dose
2 g/kg divided over 2 to 5 days
Patient failed to respond or has contraindications to corticosteroids
Dose
1 g/kg daily for 2 days every 4 to 6 weeks
Patient must meet both of the following criteria
- Cared for in consultation with a pediatric Neurologist
AND - Used in conjunction with immunosuppressives and/or plasmapheresis
Dose
1 g/kg daily for 2 days
IVIG is used as a short term, temporizing measure
Dose
2 g/kg daily for 2 days
Order must be in consultation with a pediatric Neurologist
Dose
1 to 2g/kg per month
Patient must meet both of the following criteria:
- Glucocorticoids and other 2nd line agents are contraindicated OR IVIG is part of early therapy in a critically ill child
AND - Cared for in consultation with a pediatric Rheumatologist
Dose
2 g/kg every 2 to 4 weeks
No criteria are required other than a diagnosis of Kawasaki Syndrome
Dose
2 g/kg given once
If failure to respond to initial dose, a 2nd dose may be given at least 24 hours after the 1st dose.
Patient must meet both of the following criteria:
- Is resistant to other forms of therapy
AND - Cared for in consultation with a pediatric Rheumatologist
Dose
1 to 2 g/kg every 2 to 4 weeks
Cared for in consultation with a Pediatric Rheumatologist
Dose
2 g/kg given once
Cared for in consultation with a pediatric Rheumatologist, pediatric Hematologist or pediatric Immunologist
Dose
2 g/kg given once
Patient failed to respond or has contraindications to corticosteroids
Dose
0.4 g/kg/day for 5 consecutive days every 4 weeks
Order must be in consultation with a Dermatologist
Dose
2 g/kg every 4 weeks
Patient must meet both of the following criteria:
- Failed to respond or has contraindications to high dose antihistamines
AND - Failed to respond or has contraindications to Omalizumab® (if approved)
Dose
Induction dose: 1 g/kg/day for 3 days
Maintenance dose: 1 g/kg every 4 weeks
Patient failed to respond or has contraindications to corticosteroids
Dose
2 g/kg every 4 weeks
Patient must meet both of the following criteria:
1. Treatment is at the direction of a Dermatologist
AND
2. Patient has failed to respond or has contraindications to topical steroids and calcineurin inhibitors
Dose
2 g/kg every 4 weeks
Patient must meet both of the following criteria:
- Is cared for in consultation with a Dermatologist
AND - Failed to respond or has contraindications to systemic steroids
Dose
2 g/kg every 4 weeks
(Pemphigus vulgaris, Pemphigus foliaceus, Pemphigoid, Cicatricial Pemphigoid, Linear IgA disease, Epidermolysis bullosa acquisita, Pemphigoid gestationis)
Patient must meet both of the following criteria:
- Disease is rapidly progressing
AND - Failed to respond or has contraindications to systemic steroids
Treatment is prescribed by a Dermatologist
Dose
2 g/kg every 4 weeks
Patient failed to respond or has contraindications to corticosteroids
Dose
2 g/kg every 4 weeks
Patient must be treated with a combination therapy of antibiotics and IVIG
Dose
1 g/kg on day 1 and 0.5 g/kg per day on days 2 and 3 OR 0.15 g/kg per day for 5 days
Patient must be treated with a combination therapy of antibiotics and IVIG
Dose
1 g/kg on day 1 and 0.5 g/kg per day on days 2 and 3 OR 0.15 g/kg per day for 5 days
Immunocompromised patient with parvovirus B19 causing Pure Red Cell Aplasia
Dose
Initial dose: 0.4 to 1g/kg for 5 to 10 days
Maintenance dose: 0.4g/kg every 4 weeks
1. Susceptible pregnant individuals OR immunocompromised individuals 6 months of age and older
AND
2. IVIG should only be provided within 6 days of measles exposure
Dose
0.4g/kg given once
Patient must meet the following criterion: Pathology proven acute antibody mediated rejection
Dose
IVIG is commonly administered as part of a treatment protocol that includes plasmapheresis. 0.2 g/kg after each plasmapheresis session up to a total of 10 doses (i.e. 2 g/kg maximum cumulative dose) then reassess. Additional doses may be required depending on response.
Immunocompromised patient with parvovirus B19 causing Pure Red Cell Aplasia
Dose
Initial dose: 0.4 to 1g/kg for 5 to 10 days
Maintenance dose: 0.4g/kg every 4 weeks
Immunocompromised patient with a pathological diagnosis of BK Polyomavirus (BKV)
Dose
0.2g/kg per week for 5 doses (i.e. 1g/kg maximum cumulative dose) then reassess. Additional doses may be reguired depending on response.